Literature DB >> 11439409

Altered response to meta-chlorophenylpiperazine in anorexia nervosa: support for a persistent alteration of serotonin activity after short-term weight restoration.

G K Frank1, W H Kaye, T E Weltzin, J Perel, H Moss, C McConaha, C Pollice.   

Abstract

OBJECTIVE: Patients with anorexia nervosa (AN) have disturbances of appetite and behaviors, such as dysphoria, inhibition, and obsessions, that could be related to altered serotonin activity. To investigate such relationships, we administered meta-chlorophenylpiperazine (m-CPP), a relatively serotonin-specific drug.
METHODS: To avoid the confounding effects of malnutrition or weight loss, we studied 12 patients with restricting-type AN between 5 and 17 days after a return to a normal weight and while on a stable dietary intake. We compared them to 12 healthy control women (CW). m-CPP was administered double blind and placebo controlled.
RESULTS: Although weight restored, AN women had lower body weight and increased ratings for depression and obsessionality compared with CW. After m-CPP, AN women had an elevation in mood and a reduction in body image distortion when compared with placebo. After m-CPP, groups had similar cortisol, adrenocorticotropin (ACTH), and growth hormone responses whereas AN women had an uncertain reduction in prolactin response. DISCUSSION: These data support other studies that suggest that altered serotonin activity persists after weight restoration in AN patients. The finding that m-CPP temporarily improved mood and reduced body image distortions supports the hypothesis that altered serotonin activity may contribute to the pathophysiology of AN. Copyright 2001 by John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11439409     DOI: 10.1002/eat.1054

Source DB:  PubMed          Journal:  Int J Eat Disord        ISSN: 0276-3478            Impact factor:   4.861


  8 in total

Review 1.  Current status of functional imaging in eating disorders.

Authors:  Guido K W Frank; Walter H Kaye
Journal:  Int J Eat Disord       Date:  2012-04-25       Impact factor: 4.861

2.  Olanzapine use in adolescent anorexia nervosa.

Authors:  K Dennis; D Le Grange; J Bremer
Journal:  Eat Weight Disord       Date:  2006-06       Impact factor: 4.652

Review 3.  The 5-HT3 receptor as a therapeutic target.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Expert Opin Ther Targets       Date:  2007-04       Impact factor: 6.902

4.  Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa.

Authors:  Ursula F Bailer; Guido K Frank; Julie C Price; Carolyn C Meltzer; Carl Becker; Chester A Mathis; Angela Wagner; Nicole C Barbarich-Marsteller; Cinnamon S Bloss; Karen Putnam; Nicholas J Schork; Anthony Gamst; Walter H Kaye
Journal:  Psychiatry Res       Date:  2012-11-13       Impact factor: 3.222

5.  5-HT1A receptor activation is necessary for 5-MeODMT-dependent potentiation of feeding inhibition.

Authors:  Vikas Duvvuri; Victoria B Risbrough; Walter H Kaye; Mark A Geyer
Journal:  Pharmacol Biochem Behav       Date:  2009-05-31       Impact factor: 3.533

Review 6.  Neurobiology of anorexia and bulimia nervosa.

Authors:  Walter Kaye
Journal:  Physiol Behav       Date:  2007-11-29

7.  Serotonin transporter binding after recovery from eating disorders.

Authors:  Ursula F Bailer; Guido K Frank; Shannan E Henry; Julie C Price; Carolyn C Meltzer; Carl Becker; Scott K Ziolko; Chester A Mathis; Angela Wagner; Nicole C Barbarich-Marsteller; Karen Putnam; Walter H Kaye
Journal:  Psychopharmacology (Berl)       Date:  2007-08-11       Impact factor: 4.530

8.  Acute Stress Exposure Alters Food-Related Brain Monoaminergic Profiles in a Rat Model of Anorexia.

Authors:  Carter H Reed; Ella E Bauer; Allyse Shoeman; Trevor J Buhr; Peter J Clark
Journal:  J Nutr       Date:  2021-12-03       Impact factor: 4.798

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.